Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- Drug: Nab-paclitaxel (nP) (Cohort A, B and C)Drug: NG350A (Cohort C)
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Cancer Insight, LLC
- Target Recruit Count
- 45
- Registration Number
- NCT04787991
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Stanford University, Stanford, California, United States
Immunotherapy Vaccine and Herceptin in Breast Cancer
- Conditions
- Breastcancer
- Interventions
- Drug: GP2 peptide + GM-CSF vaccine plus trastuzumab
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Cancer Insight, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT03014076
Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Cancer Insight, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT02297698
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, LLC, Santa Monica, California, United States
🇺🇸St Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸Sibley Memorial Hospital, Washington, District of Columbia, United States
News
Dr. Elizabeth Mittendorf Outlines Vision as ASCO President-Elect to Advance Multidisciplinary Cancer Care and Workforce Support
Dr. Elizabeth Mittendorf, the 2026-2027 ASCO President-Elect, will focus on advancing multidisciplinary collaboration, broadening clinical trial access, and strengthening oncology workforce support during her presidency.